Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Randomized, Double Blind, Controlled Study With Verteporfin Photodynamic Therapy And Intravitreal Triamcinolone(IVTA) Vs Triple Therapy With Verteporfin Photodynamic Therapy, Intravitreal Triamcinolone And Intravitreal Ranibizumab In Patients With Subfoveal Choroidal Neovascularization(CNV) Secondary To Age-related Macular Degeneration(AMD)

ID
Name
APEC-0031
Description
The purpose of this study is to compare the efficacy of photodynamic therapy with verteporfin (PDT) and IVTA vs triple therapy (TT) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The investigators designed a prospective, comparative, randomized, double blind, controlled study. 15 patients with classic subfoveal choroidal neovascularization secondary to age-related macular degeneration were randomized. Triple therapy can potentially offer a new treatment modality for choroidal neovascularization in patients with macular degeneration and other diseases.
Trial arms
Trial start
2006-04-01
Estimated PCD
2006-04-01
Trial end
2006-09-01
Status
Withdrawn
Phase
Early phase I
Treatment
intravitreal injection of ranibizumab
intravitreal injection of triamcinolone
photodynamic therapy
Primary endpoint
The main outcome measures were visual acuity (VA)
mean change in lesion size
mean change in foveal thickness
Eligibility criteria
Inclusion Criteria: * Subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) * Any visual acuity Exclusion Criteria: * Previous treatment * Glaucoma
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE'}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}
Updated at
2024-05-30

1 organization

2 products

1 indication

Organization
Asociación para Evitar la Ceguera en México
Product
Ranibizumab
Indication
Subfoveal Choroidal Neovascularization
Product
Triamcinolone